Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker SNDX · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 6, 2026 | A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer… NCT07923071 · Relapsed/Refractory (R/R) Hematologic Malignancies, Acute L… Revumenib | SNDX Syndax Pharmaceuticals | Phase 1 | Not yet recruiting | 18 | Jan 2030 | Registry ↗ |
| Oct 21, 2026 | Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leuk… NCT07211958 · Acute Myeloid Leukemias Revumenib, Placebo | SNDX Syndax Pharmaceuticals | Phase 3 | Recruiting | 468 | Jun 2029 | Registry ↗ |
| Oct 9, 2026 | A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1… NCT04065399 · Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia revumenib, cobicistat | SNDX Syndax Pharmaceuticals | Phase 1/2 | Recruiting | 447 | Dec 15, 2027 | Registry ↗ |
| Sep 16, 2026 | A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid… NCT06226571 · Acute Myeloid Leukemias Revumenib, Chemotherapy Regimen | SNDX Syndax Pharmaceuticals | Phase 1 | Active, not recruiting | 96 | Feb 2027 | Registry ↗ |
| Jul 6, 2026 | Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors NCT05731947 · Colorectal Cancer, Solid Tumors Revumenib, Chemotherapy | SNDX Syndax Pharmaceuticals | Phase 1/2 | Terminated | 41 | Jun 30, 2025 | Registry ↗ |
| Jun 16, 2026 | A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (… NCT04710576 · Chronic Graft-versus-host-disease Axatilimab | SNDX Syndax Pharmaceuticals | Phase 2 | Recruiting | 296 | Apr 7, 2023 | Registry ↗ |
| Mar 27, 2026 | MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) NCT06132256 · Idiopathic Pulmonary Fibrosis Axatilimab, Placebo | SNDX Syndax Pharmaceuticals | Phase 2 | Active, not recruiting | 145 | Sep 2026 | Registry ↗ |
| Sep 15, 2025 | A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD NCT03604692 · Chronic Graft-versus-host-disease axatilimab | SNDX Syndax Pharmaceuticals | Phase 1/2 | Completed | 41 | Aug 12, 2022 | Registry ↗ |
| Sep 5, 2025 | Expanded Access Program for Revumenib NCT05918913 · Relapsed/Refractory Acute Leukemia Revumenib | SNDX Syndax Pharmaceuticals | — | No longer available | — | — | Registry ↗ |
| Mar 20, 2025 | Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC)… NCT02437136 · Non-Small Cell Lung Cancer, Melanoma entinostat, pembrolizumab | SNDX Syndax Pharmaceuticals | Phase 1/2 | Completed | 191 | Sep 29, 2022 | Registry ↗ |
| Jan 10, 2025 | Study of Radiolabeled Revumenib in Adults With Acute Leukemia NCT05406817 · Acute Leukemia Revumenib | SNDX Syndax Pharmaceuticals | Phase 1 | Completed | 9 | Nov 18, 2024 | Registry ↗ |
| Dec 4, 2024 | Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Pha… NCT02708680 · Breast Cancer Entinostat, Atezolizumab | SNDX Syndax Pharmaceuticals | Phase 1/2 | Completed | 89 | Mar 31, 2021 | Registry ↗ |
| Aug 13, 2024 | A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia NCT05326516 · Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia Revumenib, Chemotherapy Regimen 1 | SNDX Syndax Pharmaceuticals | Phase 1 | Completed | 30 | Jul 29, 2024 | Registry ↗ |
| May 17, 2024 | A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With… NCT03238027 · Solid Tumor, Metastatic Tumor Axatilimab, Durvalumab | SNDX Syndax Pharmaceuticals | Phase 1 | Completed | 45 | Nov 20, 2020 | Registry ↗ |
| Jan 10, 2024 | Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer NCT02915523 · Epithelial Ovarian Cancer, Peritoneal Cancer entinostat, avelumab | SNDX Syndax Pharmaceuticals | Phase 1/2 | Completed | 140 | Feb 21, 2019 | Registry ↗ |
| Jul 6, 2023 | A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carc… NCT00750698 · Non Small Cell Lung Cancer Entinostat, Erlotinib | SNDX Syndax Pharmaceuticals | Phase 2 | Terminated | 8 | May 2010 | Registry ↗ |
| Aug 22, 2022 | Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With… NCT00602030 · Non-Small-Cell Lung Carcinoma, Carcinoma, Non-Small Cell Lu… Entinostat, Placebo | SNDX Syndax Pharmaceuticals | Phase 1/2 | Completed | 141 | Feb 4, 2010 | Registry ↗ |
| Jul 22, 2022 | A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement S… NCT04415073 · Coronavirus, COVID SNDX-6352, Placebo | SNDX Syndax Pharmaceuticals | Phase 2 | Terminated | 1 | Jul 13, 2020 | Registry ↗ |
| Jun 30, 2022 | Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI)… NCT00828854 · ER+ Breast Cancer Entinostat, Aromatase Inhibitor (AI) Therapy | SNDX Syndax Pharmaceuticals | Phase 2 | Completed | 27 | Nov 24, 2009 | Registry ↗ |
| Jun 6, 2022 | A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in… NCT00754312 · Breast Cancer SNDX-275 | SNDX Syndax Pharmaceuticals | Phase 1 | Terminated | 1 | Feb 28, 2009 | Registry ↗ |
| May 11, 2022 | Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal… NCT00676663 · Breast Cancer, Estrogen Receptor-Positive Breast Cancer entinostat, exemestane | SNDX Syndax Pharmaceuticals | Phase 2 | Completed | 130 | Jan 29, 2011 | Registry ↗ |
| Apr 28, 2022 | Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors NCT02897778 · Neoplasms, Neoplasms, Glandular and Epithelial Entinostat, Placebo | SNDX Syndax Pharmaceuticals | Phase 1 | Completed | 30 | Mar 13, 2017 | Registry ↗ |
| Jan 25, 2022 | Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid… NCT02909452 · Neoplasms, Neoplasms, Glandular and Epithelial Entinostat, Pembrolizumab | SNDX Syndax Pharmaceuticals | Phase 1 | Completed | 30 | Jul 17, 2019 | Registry ↗ |
| Dec 15, 2021 | Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Ca… NCT02820961 · Breast Cancer, Estrogen Receptor Positive Breast Cancer entinostat, exemestane | SNDX Syndax Pharmaceuticals | Phase 1 | Completed | 61 | Sep 10, 2018 | Registry ↗ |
| Nov 19, 2021 | Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non… NCT01594398 · Lung Cancer, Non Small Cell Lung Cancer (NSCLC) entinostat, entinostat | SNDX Syndax Pharmaceuticals | Phase 1 | Completed | 14 | Apr 2014 | Registry ↗ |
| Oct 22, 2019 | A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgki… NCT00866333 · Hodgkin's Lymphoma Entinostat | SNDX Syndax Pharmaceuticals | Phase 2 | Terminated | 49 | Feb 8, 2013 | Registry ↗ |
| Aug 16, 2018 | A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects NCT03187015 · Drug Interaction, Healthy Volunteer Entinostat, Midazolam | SNDX Syndax Pharmaceuticals | Phase 1 | Completed | 26 | Jun 4, 2017 | Registry ↗ |
| Aug 16, 2018 | Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat NCT02922946 · Volunteers, Healthy Volunteers Entinostat | SNDX Syndax Pharmaceuticals | Phase 1 | Completed | 47 | May 20, 2017 | Registry ↗ |
| Aug 16, 2018 | A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokine… NCT02922933 · Volunteers, Healthy Volunteers entinostat, Omeprazole | SNDX Syndax Pharmaceuticals | Phase 1 | Completed | 66 | Apr 19, 2017 | Registry ↗ |
| Apr 13, 2018 | A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired R… NCT03192111 · Renal Impairment, Healthy Volunteer Entinostat | SNDX Syndax Pharmaceuticals | Phase 1 | Completed | 40 | Nov 23, 2017 | Registry ↗ |
30 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 9:41 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances